A genetic medicine company developing scalable, one-time curative in-vivo gene editing therapies based on a mutation-agnostic editing technology.
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Pre Seed Zurich-based Immitra Bio completed an upsized 2.58 million euro pre-seed financing to fund preclinical proof-of-concept work on its in-vivo gene editing platform. Backbone Ventures led the round and OCCIDENT co-led, with several life science investors participating. | $2.8M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.